| Biomarker ID | 609 |
| PMID | 21400514 |
| Year | 2011 |
| Biomarker | miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 145 |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miRNA- 375):-DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome Pathways Include(miRNA-143):- DNA-binding transcription factor activity; Senescence and Autophagy in Cancer; Glioma; Focal adhesion; Melanoma Pathways Include(miR-145):- positive regulation of transcription by RNA polymerase II; DNA-binding transcription activator activity, RNA polymerase II-specific; positive regulation of gene expression; Pancreatic adenocarcinoma pathway; positive regulation of cell population proliferation |
| Experiment | Prostate Cancer Vs Normal |
| Type of Biomarker | Diagnostic |
| Cohort | Patient Set 1 had 26 samples having prostate cancer and their adjacent non tumor samples. GEO accession: GSE23022 |
| Senstivity | NA |
| Specificity | NA |
| AUC | miRNA- 375 0.753(95% CI: 0.623–0.883); miRNA 143 0.776 (95% CI: 0.645–0.906); miRNA 145 0.800 (95% CI: 0.678–0.921) |
| Accuracy | miRNA- 375 (67.3%) ; miRNA 143 (71.2%); miRNA 145 (71.2%) |
| Level Of Significance | miRNA- 375 (p=0.002) ; miRNA-143 (p=0.001); miRNA-145 (p<0.0001); |
| Method Used | quantitative real-time PCR |
| Clinical | No |
| Remarks | Patients divided into 2 sets - 26 and 50 patients. miRNA biomarkers were evaluated on both sets individually and combined |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | miRNA- 375, miRNA-143, miRNA-145 |